CCR2 and prostate carcinoma: The mRNA and protein expression of CCR2 were higher in aggressive cell lines such as DU145, PC-3, and C4-2B compared with androgen-sensitive LNCaP cells and non-neoplastic prostate epithelial cells [8, 54], and higher in prostate cancer metastatic tissues as compared with localized prostate cancer and benign prostate tissue [43].